Cabozantinib (Cabometyx)

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses: Cabozantinib (Cabometyx): 40 mg once daily, oral tablet Nivolumab (Opdivo): 240 mg every 2 weeks, 30-minute IV infusion, or 480 mg every 4 weeks, 30-minute IV infusion. Indication: Cabozantinib, in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic renal cell carcinoma.